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The open reading frames ORF 52, ORF 65, K12, and K8.1 of the human herpesvirus 8 (HHV8) were expressed as
glutathione-S-transferase (GST) fusion proteins and analysed by Western blotting (WB) and enzyme-linked immunosorbent
assay (ELISA). The open reading frame (ORF) 65 and K8.1 antigens gave the highest reactivity (71%) in sera from
HIV-dependent Kaposi’s sarcoma (KS) patients. Therefore both antigens appear to be essential for HHV8 diagnostics,
whereas ORF K12 and ORF 52 were of minor importance. Using polymerase chain reaction (PCR) out of the peripheral blood
of these KS patients, 48% were detected as positive. By testing an N-terminal-deleted construct (amino acid 80–171) of ORF
65, we could show that the N-terminal region of this protein is essential to mediate full immunogenic reactivity. By analysing
different deletion mutants of ORF K8.1, the major epitope was found to be located between aa 29 and 101. The prevalence
of antibodies directed against the different antigens was determined for healthy blood donors to be 3–6%. The different
antibody patterns obtained in HIV-patients with and without KS support the hypothesis that different antibody profiles develop
during the course of KS. © 1999 Academic Press
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DNA fragments of the Kaposi’s sarcoma-associated
erpesvirus (KSHV), also termed human herpesvirus 8
HHV8), were found by representational difference anal-
sis (RDA) in DNA preparation of Kaposi’s sarcoma (KS)
issue from an HIV-infected individual (Chang et al.,
994). The nucleotide sequence of the virus genome
omprises ;140.5 kb and consists of $81 open reading
rames (ORFs) (Russo et al., 1996). Based on the organi-
ation of the HHV8 genome and DNA sequence homol-
gy with other herpesviruses like Epstein–Barr virus
EBV) and Herpesvirus saimiri (HSV), HHV8 belongs to
he gammaherpesviruses (Moore et al., 1996; Russo et
l., 1996 ). The detection of HHV8 DNA in nearly all
iopsies of HIV-associated and nonassociated KS pa-
ients gave evidence that HHV8 plays a role in the patho-
enesis of KS (Dupin et al., 1995; Huang et al., 1995;
hitby et al., 1995; Moore et al., 1996). Furthermore
HV8-specific DNA was found in biopsies of other ma-
ignant diseases like AIDS-associated body-cavity-based
ymphoma (BCBL) (Cesarman et al., 1995), certain forms
f Castleman’s disease (Soulier et al., 1995), and angio-
arcoma (Gyulai et al., 1996), indicating that the virus
1 To whom reprint requests should be addressed at Biotest Ag,
andsteinerstr. 5, D-63303 Dreieich, Germany. Fax : (149)-6103–801-t35. E-mail: forschung_ag@biotest.de.
47ight be involved in other human proliferative disorders.
owever, it has to be proven whether HHV8 is the real
nducing agent of these tumors (Cohen, 1995). On the
ther hand, the prevalence of the virus in the normal
opulation is controversial. Some groups were able to
mplify virus DNA from the peripheral blood and semen
f healthy blood donors by using PCR (Bigoni et al., 1996;
onini et al., 1996), whereas others could not confirm
hese results (Li et al., 1995Howard et al., 1997). Mean-
hile serological tests might help to solve these prob-
ems because virus-specific serology is an approved
pproach for epidemiological studies. Serological data
rom immunoblotting (IB) (Gao et al., 1996; Miller et al.,
996), immunofluorescence (IF) (Gao et al., 1996 ; Kedes
t al., 1996; Lennette et al., 1996), and enzyme-linked
mmunosorbent assay (ELISA) (Andre´ et al., 1997; Davis
t al., 1997) became available. Unfortunately the interas-
ay variation of these assays is relatively high in partic-
lar when sera from patients with asymptomatic HHV-8
nfections were analysed (Rabkin et al., 1998). Some of
hese assays are based on B-cell lymphoma cell lines
eing infected either simultaneously by HHV8 and EBV
r with HHV8 alone. It has been reported that the ex-
ression of HHV8-specific antigens could be enhanced
y chemical induction to gain more sensitivity of various
ests (Miller et al., 1996).
The major immunogenic antigens identified so far arehe latency-associated nuclear antigens (LANA) p226
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48 LANG ET AL.nd p234, corresponding to ORF 73 protein (Gao et al.,
996; Kedes et al., 1997), the ORF 65 protein, which is
omologous to the EBV capsid antigen BFRF3 (Simpson
t al., 1996), and a protein termed p40, which is ex-
ressed after chemical induction of BC-1 cells (Miller et
l., 1996). Antibodies from the blood of HIV-1-infected
ndividuals with KS are directed against LANA and ORF
5 in 80% (Kedes et al., 1997) and 84% (Simpson et al.,
996), respectively. Other antigens like the minor capsid
rotein ORF 26 and ORF 52 have been reported to me-
iate lower antigenic reactivities (Simpson et al., 1996;
ndre´ et al., 1997).
Quite recently the ORF K8.1 was identified which is
ocated at nucleotide position 76,214–76,994 (Raab et al.,
998) within the HHV8 genome. ORF 8.1 codes for a 35-
o 37-kDa protein that is most likely located within the
nvelope of the virus and appears to be a major target for
uman antibodies (Raab et al., 1998). In this study, the
mmunogenic properties of different HHV8 proteins were
valuated. The proteins of ORF K8.1, ORF 65, ORF 52, and
RF K12 (Kaposin) were expressed as glutathione- S-
ransferase (GST) fusionproteins in Escherichia coli. The
usionproteins were purified and tested by Western blot
WB) analysis and by ELISA. Sera from HIV-infected pa-
ients with and without KS and from randomly selected
lood donors were used. The aim of this study was to
dentify highly reactive recombinant antigens of HHV8,
hich can be used in ELISA to allow reliable sensitive
nd specific diagnostic and epidemiological studies.
RESULTS
rocaryotically expressed K8.1b and K8.1g are equally
eactive with human sera
Three transcripts have been identified at the K8.1 locus
y RT–PCR. Transcripts K8.1a and K8.1b are generated
y alternative splicing and comprise two exons each.
hey share the same 39 exon, but the 59 exon of K8.1a
ontains an in-frame deletion relative to the 59 exon of
8.1b. As the complete coding sequence of K8.1a is also
art of the larger K8.1b, it can be assumed that all sera
hat react with K8.1a also would react with K8.1b. The
hird transcript, termed K8.1g for “genomic,” however, is
nspliced. Translation of K8.1gamma shifts to a different
aster at the position of the splice donor by K8.1b. We
hus wanted to compare the reactivity of human sera
gainst K8.1b and K8.1g. Sera (150) from both KS patients
nd patients not at risk of KS were used to measure
ntibodies against histidine-tagged, recombinant K8.1b
nd K8.1g in an ELISA. This revealed that the reactivity of
oth proteins with human sera is essentially identical.
hen the same cutoff values were used for both K8.1b
nd K8.1g, 139 of the 150 sera (92.6%) scored identical in
oth assays (Table 1). The 11 sera that scored positive in
ne assay but negative in the other always had ODeadings ,0.15 OD above the cutoff value in the positive cssay. This also is reflected by the close correlation of
8.1b and K8.1g OD values (Pearson correlation coeffi-
ient: 0.912; P , 0.01). The immunogenic epitopes of K8.1
herefore must be located in the first exon of K8.1b, which
s identical to the N-terminal part of the putative K8.1g.
or technical reasons, we used the GST fusion protein of
8.1g for comparison with other HHV-8 GST fusion pro-
eins.
loning and expression of HHV8 GST antigens
DNA fragments of different proteins of HHV8 were
mplified by PCR and cloned into a GST expression
ector. The resulting GST fusion proteins are shown
chematically in Fig. 1A. The open reading frames ORF
5, ORF 52, and K12 were completely expressed as one
iece of the corresponding protein comprising aa 1–170,
–131, and 1–60, respectively.
The DNA-fragment of ORF K8.1 was cloned without the
-terminal leader peptide of the protein. Therefore the
mino acid sequence encoded by the cloned sequence
tarts at aa 29 and ends at aa 197. All GST-fusion pro-
eins were expressed in Escherichia coli and purified to
ear homogeneity as demonstrated by sodium dodecyl
ulfate–polyacrylamide gel electrophoresis (SDS–PAGE;
ig. 1B). In addition to the full-length construct of ORF 65
n N-terminal truncated protein was assembled that
pans the C-terminal part of the protein from aa 80 to
70. It was shown previously that the major epitopes of
RF 65 are located within this region (Simpson et al.,
996). The truncated GST ORF 65 protein (ORF 65mut)
as expressed in E. coli, and the crude bacterial lysate
as analysed by Western blotting in parallel with ORF 65.
estern blot analysis
The selected GST fusion proteins were analysed in
estern blot analysis (WB) using 7 sera from HIV-1-
nfected patients (CD4 . 250/ml) with the clinical mani-
estation of KS (Table 2). The GST protein was used as a
TABLE 1
Reactivity of Human Sera with Recombinant K8.1b and K8.1g
K8.1g
Total1 2
8.1b
1 n 48 6 54
percentage of K8.1b 88.9% 11.1% 100%
2 n 5 91 96
percentage of K8.1b 5.2% 94.8% 100%
Total n 53 97 150
percentage of K8.1b 35.3% 64.7% 100%
Note. x2 (Pearson): 105.915; P (two sided) , 0.0001; n 5 number of
amples.ontrol and did not react with any of the samples. ORF 65
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49HHV-8 ANTIGENSave a positive reaction with five of seven sera. For two
f these five positive samples ORF 65 gave the only
isible band indicating that samples exist, which exclu-
ively react with ORF 65. On the other hand ORF 65 was
ompletely negative with two other samples out of this
anel. ORF 52 mediates only a faint band with two of
even samples, indicating that ORF 52 is less reactive
han ORF 65 (Table 2). With the ORF K12 protein, the
ame result as shown with ORF 52 was obtained. Only
wo faint bands were visible in two of seven samples. All
ther sera were completely negative with ORF 52 and
12, indicating that both polypeptides ORF 52 and K12
an not supplement K8.1 and ORF 65. The ORF K8.1 gave
trong reactions with five of seven (71%) samples medi-
ting the same reactivity with this panel as ORF 65 (Table
). Again two samples exclusively reacted with this pro-
ein. That means that K8.1, similar to ORF 65, appears to
e a valuable antigen to detect HHV8-specific antibod-
es. To localise the immunogenic regions of ORF 65 and
8.1, a series of deletion mutants of ORF 65 (ORF 65mut)
nd ORF 8.1 (K8.1 mut1, K8.1 mut2, and K8.1 mut3) was
xpressed as GST-fusion proteins (Table 3). All polypep-
ides were expressed in E. coli, and a crude bacterial
ysate was analysed in WB assays using six sera from
IV1/KS1 individuals. Three samples out of this panel
TABLE 2
Postive Reactions in Western Blot with Recombinant ORF 65, 52,
K12 and K8.1 Protein and Sera From HIV-Dependent KS Patients
Sample serum No. of samples ORF 65 ORF 52 K12 K8.1
HIV1/KS1a 7 5 2 2 5
band pattern 111b 1c 1 111
a HIV-positive patients with Kaposi’s sarcoma.
b Strong band in Western blot.
c Faint band in Western blot.
T
Deletion Mutant Analysis of ORF 65 and ORF K8
ORF aa
aa a-170
5
aa 80-170
5 mut
aa 29-197
8.1
aa 101-197
8.1 mut 1
aa 29-158
8.1 mut 2
aa 29-120
8.1 mut 3ave a clear reaction with the mutated ORF 65 protein,
hereas all other sera were completely negative. This
xperiment demonstrates that both the C-terminal part
nd the N-terminal 80 aa of ORF 65 are necessary to
aintain the full immunogenic reactivity of this antigen.
oncerning the K8.1 antigen, all sera reacted with the
-terminal part extending from aa 29 to 120. No band
ould be seen with the C-terminal region comprising aa
01–197, indicating that an immunoreactive epitope is
ocalised within aa 29–101.
LISA experiments
After initial WB analysis, we wanted to compare se-
ected recombinant proteins of HHV8 with a higher num-
er of samples. Therefore all antigens were coated to
icrotiter plates in the same amount (1 mg/ml) to perform
LISA. At first each antigen-specific ELISA was tested
ith 135 samples from healthy blood donors. To define
riteria for positive and negative results, the cutoff of
ach test was calculated in the following way. The mean
D value of all nonreactive samples, representing the
ackground reactivity, was added to the standard devi-
tion multiplicated by a factor of 3. Extreme OD values
ere excluded from the calculation. The cutoffs of the
LISAs for K8.1, ORF 65, K12, and ORF 52 were 0.269,
.497, 0.362, and 0.689 OD, respectively. All sera were
ested with the GST-dependent ELISA, and samples
bove the cutoff were excluded from the evaluation.
sing these criteria, the prevalence of antibodies di-
ected against the antigens was 2.9% for ORF 65 and
12, 3.7% for K8.1, and to 6.6% for ORF 52 (Table 4). It has
o be noted, that only one sample out of this panel was
imultaneously positive with K8.1 and ORF 52 (Table 5).
he other samples were individually positive with one
ntigen only, indicating that at least part of the samples
ay represent false positive results of each antigen. We
ested 49 sera from HIV-infected KS patients. The major-
g Six Samples From HIV-Dependent KS Patient
Samples
1 2 3 4 5 6
1 1 1 1 1 1
2 2 2 1 1 1
1 1 1 1 1 1
2 2 2 2 2 2
1 1 1 1 1 1
1 1 1 1 1 1ABLE 3
.1 Usin
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50 LANG ET AL.ty of them 33/67% were positive with K8.1, 18/37% were
ositive with both ORF 65 and K12, and only 3/6.1% were
eactive with ORF 52. Simultaneously positive with K8.1
nd ORF 65 were 14 (28%) samples, and with the two
ntigens K8.1 and K12, 17 (34%) were positive (Table 5). It
s interesting to note that eight and two sera out of this
anel gave a positive OD value only with K8.1 and ORF
5, respectively. These results confirm the WB results,
ndicating that both antigens are essential for HHV8-
pecific antibody detection. No sample was found that
as positive with K12 exclusively. All K12 reactive sera
ere either reactive with K8.1 or with ORF 65. The pe-
ipheral blood of the same patients were analysed by
HV8-specific PCR. Only 25/48% showed a specific band
n the agarose gel, demonstrating that serology medi-
ted more positive results than PCR. In addition to the
anel of HIV-dependent KS patients, we tested two se-
ies of sera from homosexual (HS) HIV-infected individ-
als. The patients were without any clinical manifesta-
ion of KS and came from two different geographical
reas (France and California, Table 4). With K8.1, 23.5 and
3.5% of the sera were positive in the French and US
roups, respectively. The same increment of positive
ates within the US group could be seen with ORF 65 and
T
ELISA Results of Recombinant ORK K8.1, 65,
Serum panel HIV KS
No. of
samples K
lood donors
Germany 2 2 135 5 (
S patients
France 1 1 49 33 (
omosexuals
France 1 2 17 4 (
USA 1 2 53 39 (
Note. Parentheses enclose percentages.
T
ELISA Results of Recombinant ORF K8.1
Serum panel
No. of
samples
K8.11
651
K8.1
K12
lood donors
Germany 135 0 0
Spatients
France 49 14 (28) 17 (3
omosexuals
France 17 2 (12) 3 (1
USA 53 10 (19) 28 (5Note. Parentheses enclose percentages. The number of sample which wer12. One explanation for that could be a higher proba-
ility of the individuals to develop KS in the US group
elatively to the French group and possibly reflects the
revalence of HHV8 in metropolitan and rural countries.
n addition, the pattern of the reactive antigens was
ifferent. For instance, the reactivity of K12 was relatively
igh within the HS groups in particular in the US group
66%). There were 9 and 12 sera exclusively reactive with
12 and K8.1, respectively, whereas none of the samples
as ORF 65 positive. These results lead to the hypoth-
sis that the pattern of antibody reactivity is different
etween KS and AIDS patients without KS.
DISCUSSION
In this study, we describe the evaluation of different
roteins as recombinant antigens for serology. These
ntigens may be essential for the design of a recombi-
ant HHV8-specific ELISA. The coding sequence of
NA-fragments, of ORF 65, ORF 52, K12, and K8.1 were
xpressed as GST-fusion proteins and analysed by West-
rn blotting and ELISA. We could show that ORF 65,
hich is the gene homologous to BFRF3 of EBV, is a
ighly reactive antigen. With this protein we obtained a
nd 52 Protein with Different Service Panels
Number positives
PCR65 K12 52
4 (2.9) 4 (2.9) 8 (6.6) n.d.
18 (37) 18 (37) 3 (6.1) 25 (48)
2 (11.7) 3 (17.3) 1 (5.8) 2 (11.6)
10 (18.8) 35 (66) 5 (9.4) n.d.
12, and 52 Based on Tables on Table 3
Number positives
K8.11
521
651
K121
651
521
521
K121
1 (0.7) 0 0 0
3 (6) 9 (18) 1 (2) 2 (4)
1 (6) 2 (12) 1 (6) 1 (6)
3 (6) 6 (11) 2 (4) 3 (5.6)ABLE 4
K12, a
8.1
3.7)
67)
23.5)
73.5)ABLE 5
, 65, K
1
1
4)
8)
3)e simultaneously postive with two antigens are indicated.
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51HHV-8 ANTIGENSelatively high sensitivity by WB of seven samples from
IV-dependent KS patients, confirming the results of
impson et al. (1996). On the other hand only 37% of sera
rom HIV1/KS1 were positive with this antigen in ELISA.
ne can hypothesise that under optimised conditions
he cutoff can be improved in a way to increase the
ositive rate of this antigen. Otherwise the robustness of
his antigen has to be taken into account, as well. The
ST ORF 65 is expressed as a rather insoluble protein
nd has to be purified under denaturing conditions, i.e.,
sing urea and SDS. Loss of reactivity due to altered
onfirmation during purification or reduced coating ca-
acity of the SDS-treated antigen can not be excluded.
nalysing the N-terminal deletion mutant of ORF 65, it
ould be demonstrated that the removal of the first 80
mino acids of the protein results in substantial loss of
eactivity. Only 20% of the sera tested in WB gave a clear
esult with the C-terminal region, suggesting that essen-
ial epitopes are located in the N-terminal part of the
rotein. As the N-terminal region of ORF 65 is 40% ho-
ologous to BFRF3 of EBV, we tested seven highly pos-
tive sera from nasopharyngeal carcinoma (NPC) pa-
ients to confirm specificity. Although these samples
ave high titers of antibodies against BFRF3 protein, we
id not detect any cross-reactivity with EBV (data not
hown).
In comparison with ORF 65, we evaluated the ORF
8.1, which was identified recently as immunogenic pro-
ein (Raab et al., 1998). ORF K8.1 codes for a 35- to
7-kDa glycosylated protein, which is likely to be located
n the envelope of HHV8. Our data suggest that gp35/37
s a highly immunoreactive antigen. In WB analysis 71%
nd in ELISA 67% of KS sera were positive with this
olypeptide. The fact that 18% of the sera tested in ELISA
xclusively reacted with gp35/37 demonstrates that this
ntigen is important for serological diagnosis of HHV8
nfection. By deletion mutant analysis we have shown
hat one or more epitopes are located within the N-
erminal region of the protein within aa 29 and 101. The
nalysis of the mRNAs transcribed from the K8.1 has
hown that two spliced mRNA fragments termed K8.1b
nd K8.1a exist. The intron sequence of the first splice
onor started with aa 83 (Raab et al., 1998). Therefore it
s very likely that the immunogenic domain is localised
ithin aa 30 and 82.
In addition to ORF 65 and K8.1, we presented data
oncerning the 60 amino acid protein K12 also termed
aposin. The corresponding 700-nucleotide RNA (T0.7)
as documented to be detected by in situ hybridisation
n every KS tumor examined so far (Staskus et al., 1997).
ith the K12 protein, we could observe 37% positivity in
era from HIV-dependent KS patients but #66% positive
amples in HIV-infected homosexuals without KS. We
bserved different positivity rates testing individuals with
nd without KS. Most interesting is the high frequency of
HV-8-specific antibodies in risk groups, like the homo- Aexual HIV-positive men. Anti-K12 is very frequent in
hese groups. Unfortunately no follow-ups were available
rom homosexual individuals, who were K12 reactive. A
rospective study has to be initiated to establish the
redictive value of K12-antibody reactivity for the devel-
pment of KS.
In conclusion, the recombinant antigens gp35/37
nd ORF 65 are valuable reagents to improve HHV8
erology. The design of the assay based on these
ecombinant proteins has to be improved and addi-
ional antigens have to be added to enhance sensitiv-
ty of an ELISA, which is based on these recombinant
ntigens.
MATERIALS AND METHODS
xpression of recombinant proteins
The DNA fragments of different open reading frames
f HHV8 were cloned by PCR and expressed as GST
roteins. For cloning of ORF 65, which is the gene ho-
ologous to the immunoreactive ORF BFRF3 of EBV (van
runsven et al., 1994), primer CAGGATCCG TATGTC-
AACTTTAAGGTG at the 5 primed end and primer
CAAGCTTCAATTGCTATTT CTTTTTGCCAGAGGG at
he 39 primed end is used. The amplification product,
hich represents amino acid (aa) 1–170 of ORF 65, was
leaved by using the restriction enzymes (RE) BamHI and
unI. The DNA fragment was ligated with the GST ex-
ression vector pGEX-3 (Pharmacia Biotech, Uppsala,
weden), which was cleaved with BamHI and EcoRI. In
dditional to the ORF 65 full-length protein, an N-terminal
eleted variant of ORF 65 (ORF 65mut) was cloned using
he following DNA oligonucleotide, AGGATCCGTAAAC-
GCGCGAGCGCGCT as a 59 primer within the PCR
eaction. The same primer at the 39 end and the same
estriction enzymes were used as mentioned above. The
esulting GST protein comprises aa 80–170 of ORF 65.
or cloning of ORF 52 (aa 1–132), the primer pair
TAAGCTTAGATCTGTATGGCCGCGCCCAGGGGC/CGG-
ATTCCTAGGGGATCCCGTCATCAACCCCCGCCCG was
sed. The amplified PCR product was cleaved with BglII
nd EcoRI and ligated to pGEX-3, which had been mod-
fied before with BamHI and EcoRI. ORF K12 (aa 1–60)
lso termed kaposin was assembled by using PCR
rimer CAGGATCCGTATGGATAGAGGCTTAACGGTGT
nd CGGAATTCCTAGATCTCGT GCGCGCCCGTTGCAA-
TCG. PCR product was treated with RE BamHI and
coRI and ligated with pGEX-3, which was cleaved with
he same enzymes. For cloning of ORF K8.1 (aa 29–197),
CR was performed with the primer pair CAGGATC-
GTCCCACG TATCGTTCGCATTTG/CGGAATTCCT-
GATCTCTTTCTGCCGTTTTCTGCGACCGGTGATACGC-
AGTTCGC deleting the internal EcoRI site at the 39 end
f the ORF K8.1. A series of deleted ORF K8.1 protein was
loned by using the following primer pairs: GAGCGCAT-
GTGGCCAGCGTCTTTTGCCGTCTTTCTCTAGATCC-
T
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52 LANG ET AL.TAAGGC/CAGGATCCGTGATGCAATAGATGAATCG for
8.1 mut 1 (aa 101–197), CAGGATCCGTCC CACG-
ATCGTTCGCATTTG/CGGAATTCCTAGATCTCACCGA-
GGTTTACCCAAT for K8.1 mut 2 (aa 29–158) and primer
air CAGGATCCGTCCCACGTATCGTT CGCATTTG/CG-
AATTCCTAGATCTCAGTCACGTGGGAGGTCACGGG for
8.1 mut 3 (aa 29–120). The amplified PCR products were
leaved with BamHI and EcoRI and ligated to pGEX-3,
hich was cleaved before with BamHI and EcoRI. All
ST fusions were expressed in E. coli and purified to
ear homogeneity (Fig. 1B) with the exception of the
eleted antigens of ORF 65 and ORF K8.1, which were
FIG. 1. (A) overview of the open reading frames (ORF) 65, 52, K8.1, an
f the purified recombinant proteins. GST was used as a negative con
espectively. A molecular weight marker is shown in lane M.sed as crude E. coli lysates. Hxpression and purification of histidine-tagged
ecombinant proteins
A cDNA fragment coding for K8.1b was amplified from
CBL-1 cells using oligonucleotides K8.1-rt59 Bam (GATC
GA TCC AAT TGT CCC ACG TAT CGT TC) and K8.1-h1
GAT C A AGC TTA TGG CTC CGT ATT TCT TT) and
loned into the prokaryotic expression vector pQE9
Quiagen Inc., Hilden, Germany) via BamHI and HindIII
estriction sites. The resulting expression plasmid en-
odes amino acids 27–196 of K8.1b and an N-terminal
ag containing six histidine residues (MRGSHHHHH-
hich were expressed as GST fusionproteins in E. coli. (B) SDS–PAGE
ne 1). GST ORF 65, 52, K12, and K8.1 were run in lane 2, 3, 4, and 5d 12, w
trol (laGS). A DNA fragment encoding K8.1g was amplified
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53HHV-8 ANTIGENSrom genomic HHV-8 DNA using oligonucleotides
8.1mBam (GTG CGG ATC CAA TTG TCC CAC GTA TCG
TC) and K8.1HindR (GGC AAA GCT TGG CAC ACG GTT
CT AGC ACC) and cloned into pQE9 after digestion with
amHI and HindIII. Recombinant proteins were ex-
ressed in E. coli strain M15prep4 and purified by Ni-
ffinity chromatography as previously described (Raab et
l., 1998). The resulting proteins were purified further by
everse-phase liquid chromatography (RPLC). For RPLC,
8.1b- or K8.1-containing fractions from Ni-chelate affinity
hromatography were adjusted to 0.1% trifluoracetic acid
nd applied to an FPLC column (Pharmacia) containing
i-Chroprep RP-18 matrix (Merck Inc.). After washing with
hree column volumes of 0.1% trifluoracetic acid, protein
as eluted by a continuous isopropanol gradient (20–
0%). Isopropanol was removed by dialysis and the pro-
ein concentration was determined using the BCA assay
Pierce Inc.).
CR and Southern blot hybridisation
Blood samples from HIV-infected patients with and
ithout KS were examined for HHV8-specific DNA by
CR at Groupe Hospitalier Pellegrin (Bordeaux, France).
fter thawing, DNA was extracted from the samples by a
tandard phenol/chloroform extraction procedure. All
NA samples were confirmed to be amplifiable by PCR
rimers specific for a conserved region of the human
b-globin gene. The primers for PCR were specific for a
33-bp (KS 330233) DNA fragment. The reaction condi-
ions were performed and confirmed by Southern blot
ybridisation as described previously (Dupon et al.,
997).
estern blot analysis
Western blot (WB) analysis was performed with crude
ysates or purified recombinant GST fusionproteins as
escribed by Baur et al. (1992). To use equal amounts of
rotein during sodium dodecyl sulfate (SDS) polyacryl-
mide gel electrophoresis (PAGE), the protein samples
ere diluted until the intensity of the bands was compa-
able by visualisation after Coomassie blue staining.
urified GST was run as a control in each WB analysis.
fter separation of the proteins by SDS–PAGE (15%), the
olypeptides were transferred to polyvinylidine difluoride
embranes (Millipore) under semidry conditions. Mem-
ranes were blocked for 1 h with 1% bovine serum
lbumin (Sigma) and incubated overnight with 1:200 di-
uted human sera. After washing the membranes, bound
mmunoglobulin G (IgG) was visualised by using horse-
adish peroxidase (HRP)-conjugated polyclonal rabbit
nti-human IgG and diaminobenzidine as a substrate.
LISA analysis
Selected HHV8 GST fusionproteins were purified and
urther analysed by ELISA. Soluble antigens were puri-ied after lysis of bacteria via glutathione–sepharose
ffinity chromatography. Insoluble proteins were purified
y differential washing and centrifugation steps using
ariable concentrations of detergents and chaotropic re-
gents at different pH values followed by ionexchange or
elchromatography (Gorgievski-Hrisoho et al., 1990) The
ntigens have been coated onto 96-well polystrene mi-
rotest plates in a concentration of 1.0 mg/ml according
o a standard procedure (Vornhagen et al., 1994). Sera
1:21 diluted) were incubated for 60 min at 37°C. After
ashing, the conjugate, a murine anti-human IgG mono-
lonal antibody (BS12, Biotest) labeled with HRP, was
ncubated at 37°C for 30 min. After another washing, the
nzyme reaction was performed for 30 min at room
emperature using a ready-to-use TMB reagent (Sigma).
eaction was stopped with 1 N sulphuric acid and ab-
orbence was read at 450 nm using a reference wave-
ength of 690 nm. Cutoff values were set for each antigen
t 300 m OD. As a reference a commercially available
LISA for detection of anti-HHV8 IgG antibodies was
sed.
erum samples
Sera from healthy blood donors were obtained from
he German red cross center (Frankfurt, Germany). Sera
rom HIV-infected patients with and without KS from
rance were obtained by Laboratory of Systematic and
olecular Virology, Hopital Pellegrin (Bordeaux, France).
he sera from homosexual HIV-infected patients were
ommercially available (BioClinical Partners, Franklin
A). Sera from HIV-infected KS Patients were addition-
lly obtained by the Institute for Medical Virology, Jo-
ann-Wolfgang Goethe-University (Frankfurt/Main, Ger-
any).
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